CD274 and melanoma: The FDA (Food and Drug Administration) has already approved immune checkpoint inhibitors, such as ipilimumab (an anti-CTLA-4 MoAbs), nivolumab, and pembrolizumab (anti-PD-1 MoAbs) or atezolizumab, avelumab, and durvalumab (anti-PD-L1 MoAbs) for different types of cancer, like melanoma, lung cancer, and renal cell carcinoma.